Holen Sie sich die Stockscreener-App
1.57
1.29%
0.02
Handel nachbörslich:
1.51
-0.06
-3.82%
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Inhibikase Therapeutics Reports Q3 2025 Financials and Progress - TipRanks
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million By Investing.com - Investing.com Australia
Sands capital buys Inhibikase therapeutics (IKT) shares worth $3 million - Investing.com India
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - The Globe and Mail
Inhibikase Therapeutics Inc IQT0 Stock Analysis and ForecastGrowth Stock Opportunities & Interactive Learning for Better Returns - earlytimes.in
Four companies raise nearly $950M in follow-ons: Public Equity Report - biocentury.com
[8-K] Inhibikase Therapeutics, Inc. Reports Material Event | IKT SEC FilingForm 8-K - Stock Titan
[424B5] Inhibikase Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Net current asset value per share of Inhibikase Therapeutics, Inc. – MUN:IQT0 - TradingView
Inhibikase Shares Climb After Revised Drug Timeline, Public Offering - MarketScreener
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksJuly 2025 Outlook & Short-Term Trading Alerts - newser.com
Inhibikase Therapeutics Prices $100 Million Public Offering - MarketScreener
Inhibikase Therapeutics (IKT) Prices $100 Million Public Offerin - GuruFocus
Is Inhibikase Therapeutics Inc. stock a buy before product launchesJuly 2025 Drop Watch & Fast Moving Trade Plans - newser.com
Inhibikase Therapeutics, Inc. (IKT) Stock: Declines Amid $100 Million Public Offering Announcement - parameter.io
Inhibikase Therapeutics (NASDAQ: IKT) prices $100M stock, warrants offering at $1.45 - Stock Titan
Inhibikase Therapeutics announces proposed public offering and pre-funded warrants - MSN
IKT Announces Pricing Below Previous Closing Price in Latest Off - GuruFocus
Is Inhibikase Therapeutics Inc. reversing from oversold territoryTrade Signal Summary & Daily Momentum Trading Reports - newser.com
Inhibikase Therapeutics prices $100 million public offering - Investing.com
Inhibikase Therapeutics prices $100 million public offering By Investing.com - Investing.com Australia
Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics prices public offering of 46 million shares at $1.45 per share - MarketScreener
IKT Announces New Offering Managed by Leading Financial Firms - GuruFocus
Inhibikase Therapeutics (IKT) Launches Public Offering of Common Stock - GuruFocus
Inhibikase Therapeutics announces proposed public offering of common stock and pre-funded warrants - MarketScreener
Inhibikase Therapeutics (IKT) Launches Public Stock Offering - GuruFocus
Inhibikase Therapeutics (IKT) Plans Global Phase 3 Trial for PAH Treatment - GuruFocus
Inhibikase Therapeutics stock falls after announcing public offering By Investing.com - Investing.com South Africa
Inhibikase Therapeutics stock falls after announcing public offering - Investing.com India
Inhibikase Therapeutics Advances IKT-001 to Phase 3 Study - TipRanks
Inhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Inhibikase Therapeutics to Initiate Pivotal Phase 3 Study for IKT-001 in Pulmonary Arterial Hypertension, Potentially Accelerating FDA Approval Timeline - Quiver Quantitative
Inhibikase (NASDAQ: IKT) starts stock, pre-funded warrant offering with 30-day 15% option - Stock Titan
Inhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension - GlobeNewswire
Inhibikase Therapeutics (Nasdaq: IKT) Plans Single Pivotal Phase 3 PAH Trial of IKT-001 - Stock Titan
Signal strength of Inhibikase Therapeutics Inc. stock in tech scanners - newser.com
Using data models to predict Inhibikase Therapeutics Inc. stock movementRecession Risk & Scalable Portfolio Growth Ideas - newser.com
Top chart patterns to watch in Inhibikase Therapeutics Inc.Recession Risk & Low Risk Entry Point Tips - newser.com
Is Inhibikase Therapeutics Inc. (IQT0) stock overpriced at current multiples2025 Market Outlook & Smart Money Movement Tracker - newser.com
Why Inhibikase Therapeutics Inc. (IQT0) stock fits value portfolios2025 Geopolitical Influence & Advanced Swing Trade Entry Plans - newser.com
How to build a dashboard for Inhibikase Therapeutics Inc. stock2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Can volume confirm reversal in Inhibikase Therapeutics Inc.July 2025 Weekly Recap & Free Daily Entry Point Trade Alerts - newser.com
Is Inhibikase Therapeutics Inc. stock cheap compared to fundamentalsPortfolio Value Summary & AI Based Buy/Sell Signal Reports - newser.com
Will Inhibikase Therapeutics Inc. stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - newser.com
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Opening Moves & Low Risk Entry Point Guides - newser.com
Understanding Inhibikase Therapeutics Inc.’s price movementInflation Watch & Fast Entry Momentum Alerts - newser.com
Key resistance and support levels for Inhibikase Therapeutics Inc. - newser.com
0.53%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):